Indaptus Therapeutics Inc. (INDP)
NASDAQ: INDPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INDP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $433.16M
- EPS (TTM)
- -$3.16
- Dividend yield
- None
- 52-week range
- 0.92 – 5.96
- Day range
- 2.78 – 3.16
- Volume / Avg
- 239.36K / 712.87K
- Beta
- —
- Shares outstanding
- 153.60M
52-week range
INDP stock today
Indaptus Therapeutics (INDP) closed at $2.82 on Nov 20, down 9.90% (-$0.31), versus the S&P 500's 3.70% decline. Trading was light, with 239.36K shares changing hands, about 34% of the average daily volume. Shares are 52.7% below their 52-week high of $5.96, set on Jun 4, 2026 and 206.5% above the 52-week low of $0.92, in the middle of the past year's range.
INDP is down 3.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.4%. Indaptus Therapeutics has posted a net loss over the last twelve months (EPS of -$3.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Indaptus Therapeutics
Company profileIndaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Junyi Dai
- Headquarters
- New York, NY
- Employees
- 5
- Website
- indaptusrx.com
Financial highlights
Full financialsIndaptus Therapeutics reported a net loss of $20.8 million, compared with a loss of $15.0 million a year earlier. Diluted earnings per share came in at -$21.58.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-20.85M | $-15.02M | $-15.42M | $-14.32M | $-7.71M |
| EPS (diluted) | $-21.58 | $-44.96 | $-1.83 | $-1.73 | $-1.89 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.01 vs —
INDP news
All INDP newsIndaptus Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOLSEvolus Inc. | 6.52 | -6.86% | $431.55M | vs INDP |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs INDP |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs INDP |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs INDP |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs INDP |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs INDP |
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs INDP |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs INDP |
Indexes, lists and sector
Indaptus Therapeutics stock FAQ
What is Indaptus Therapeutics's stock price today?
INDP last traded at $2.82 as of Nov 20, 4:00 PM EST, down 9.90% on the day. Prices are delayed at least 15 minutes.
Does Indaptus Therapeutics pay a dividend?
No. Indaptus Therapeutics does not currently pay a regular cash dividend.
Who is Indaptus Therapeutics's CEO?
Mr. Junyi Dai is the chief executive officer of Indaptus Therapeutics Inc., which has about 5 employees.
Has INDP ever split its stock?
Yes. The most recent INDP stock split was a 1-for-28 split on Jun 27, 2025, one of 3 splits on record.
What is the INDP 52-week high?
The 52-week high for INDP is $5.96 and the 52-week low is $0.92. The stock is currently 52.7% below its high.